TY - JOUR
T1 - The Prevalence of Symptomatic Dermographism
T2 - Results of the International UCARE PREVALENCE-D Study
AU - Kulthanan, Kanokvalai
AU - Bernstein, Jonathan A.
AU - Rudenko, Michael
AU - Salameh, Pascale
AU - Komoltri, Chulaluk
AU - Adışen, Esra
AU - Al Abri, Salma
AU - Al-Ahmad, Mona
AU - Al-Ahmed, Nasser
AU - Al Hinai, Bushra
AU - Allenova, Anastasiia
AU - Alshareef, Saad
AU - Angkoolpakdeekul, Nattha
AU - Arnaout, Rand
AU - Bartosińska, Joanna
AU - Cherrez-Ojeda, Ivan
AU - Chularojanamontri, Leena
AU - Criado, Paulo Ricardo
AU - Ensina, Luis Felipe
AU - Criado, Roberta Fachini Jardim
AU - Calle, Cesar Alberto Galvan
AU - Giménez-Arnau, Ana Maria
AU - Godse, Kiran
AU - Gotua, Maia
AU - Inomata, Naoko
AU - Jantanapornchai, Nuttagarn
AU - Jung, Chang Gyu
AU - Kasperska-Zając, Alicja
AU - Khoshkhui, Maryam
AU - Kolkhir, Pavel
AU - Krasowska, Dorota
AU - Laomoleethorn, Jomgriditip
AU - Maiorowa, Antonina
AU - Meshkova, Raisa
AU - Mijakoski, Dragan
AU - Munoz, Melba
AU - Nanchaipruek, Yanisorn
AU - Nasr, Iman
AU - Kara, Rabia Öztaş
AU - Panjapakkul, Waratchaya
AU - Paringkarn, Teerapat
AU - Podder, Indrashis
AU - Robles-Velasco, Karla
AU - Rosmaninho, Isabel
AU - Presa, Ana Rita
AU - Rujitharanawong, Chuda
AU - Saengthong-aram, Phuwakorn
AU - Tafrishi, Rana
AU - Mitrevska, Natasa Teovska
AU - Tuchinda, Papapit
AU - Wannawittayapa, Teerapat
AU - Wilson, Anushka
AU - Ye, Young Min
AU - Zalewska-Janowska, Anna
AU - Maurer, Marcus
AU - Zuberbier, Torsten
N1 - Publisher Copyright:
© 2025 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
PY - 2026/2
Y1 - 2026/2
N2 - Background: The prevalence of symptomatic dermographism (SD) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE-D (Prevalence Estimation of Dermographism) study was the largest international, cross-sectional, internet-based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert-designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD. Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex- and age-adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [CI] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD, and emphasize the need for appropriate healthcare resource allocation and disease recognition.
AB - Background: The prevalence of symptomatic dermographism (SD) in the general population remains unclear. This study aimed to internationally estimate the prevalence of SD and two other dermographic subtypes—physiological red dermographism and simple urticarial dermographism—among adults worldwide. Methods: The PREVALENCE-D (Prevalence Estimation of Dermographism) study was the largest international, cross-sectional, internet-based investigation conducted by the Urticaria Centers of Reference and Excellence of the Global Allergy and Asthma Excellence Network from 2021 to 2024. A world expert-designed questionnaire was completed by participants from 28 centers across 19 countries to diagnose SD. Participants were recruited into three age groups (18–24, 25–60, and > 60 years), with ≥ 1000 individuals per group per country. We calculated sex- and age-adjusted prevalence estimates internationally and by country, with 95% confidence intervals. Results: Among 59,543 participants worldwide, those with SD had an adjusted point prevalence of 3.20% (95% confidence interval [CI] 2.68%–3.73%) and a lifetime prevalence of 5.94% (95% CI 5.32%–6.56%). The 25–60 years group presented the highest prevalence. Females had higher rates than males, with statistically significant differences across all age groups for both point and lifetime prevalence. Physiological red dermographism had an adjusted point prevalence of 10.02% (95% CI 9.48%–10.55%) and a lifetime prevalence of 33.47% (95% CI 32.01%–34.94%). Simple urticarial dermographism showed an adjusted point prevalence of 1.21% (95% CI 1.08%–1.35%) and a lifetime prevalence of 5.39% (95% CI 4.99%–5.79%). Conclusion: These findings provide comprehensive international estimates of dermographism, particularly SD, and emphasize the need for appropriate healthcare resource allocation and disease recognition.
KW - chronic inducible urticaria
KW - dermographism
KW - prevalence
KW - symptomatic dermographism
KW - urticaria
UR - https://www.scopus.com/pages/publications/105015654737
U2 - 10.1111/all.70047
DO - 10.1111/all.70047
M3 - Artículo
AN - SCOPUS:105015654737
SN - 0105-4538
VL - 81
SP - 468
EP - 479
JO - Allergy: European Journal of Allergy and Clinical Immunology
JF - Allergy: European Journal of Allergy and Clinical Immunology
IS - 2
ER -